Pharmaceutical stocks are very tricky for me. It's like playing with huge amounts. For example, I don't understand how to value an investment opportunity for the company without revenue flow and any other incomes. Of course, you can evaluate the market, added value of the company's projects and potential products, but what if FDA doesn't approve it? What if such products will not be as efficient as they needed to be? Omeros Corporation has already some kind of a revenue flow. They just made an announcement about their new product:The OMS721 Phase 3 program will consist of one clinical trial – a single-arm (i.e., no control arm), open-label trial in patients with newly diagnosed or ongoing aHUS. The clinical package for the biologics license application (BLA) will be similar to that which formed the basis of approval for Soliris® (eculizumab). No doubts, it's good for investors and it can potentially boost the company's sales. But the risk is also huge. I think that's why such companies usually go public instead of raising venture rounds. Just a few funds want to take such risk, mostly corporate funds. Perhaps sometime later I will come to an idea that I need to put small amount of cash to pharma stocks.